Sangeeta N. Bhatia
Known title: DirectorCIK: 0001643921
Associated companies
Transaction History
| VRTX | ▼ Sell | Open Market | 318 | $135K | 5/4/2026 | View on chart |
| VRTX | ▲ Buy | Grant | 943 | $0 | 5/1/2026 | View on chart |
| VRTX | ▼ Sell | Open Market | 266 | $133K | 2/13/2026 | View on chart |
| VRTX | ▼ Sell | Open Market | 266 | $103K | 8/27/2025 | View on chart |
| VRTX | ▼ Sell | Open Market | 400 | $202K | 5/2/2025 | View on chart |
| VRTX | ▲ Buy | Grant | 796 | $0 | 5/1/2025 | View on chart |
| VRTX | ▲ Buy | Option Exercise | 646 | $99K | 8/30/2024 | View on chart |
| VRTX | ▼ Sell | Open Market | 646 | $323K | 8/30/2024 | View on chart |
| VRTX | ▲ Buy | Option Exercise | 1,292 | $197K | 8/8/2024 | View on chart |
| VRTX | ▼ Sell | Open Market | 1,292 | $602K | 8/8/2024 | View on chart |
| VRTX | ▼ Sell | Open Market | 467 | $188K | 5/2/2024 | View on chart |
| VRTX | ▲ Buy | Grant | 1,001 | $0 | 5/1/2024 | View on chart |
| VRTX | ▼ Sell | Open Market | 243 | $91K | 10/17/2023 | View on chart |
| VRTX | ▼ Sell | Open Market | 242 | $87K | 10/6/2023 | View on chart |
| VRTX | ▼ Sell | Open Market | 242 | $84K | 8/9/2023 | View on chart |
| VRTX | ▼ Sell | Open Market | 62 | $21K | 5/2/2023 | View on chart |
| VRTX | ▼ Sell | Open Market | 63 | $22K | 5/2/2023 | View on chart |
| VRTX | ▼ Sell | Open Market | 163 | $57K | 5/2/2023 | View on chart |
| VRTX | ▼ Sell | Open Market | 120 | $42K | 5/2/2023 | View on chart |
| VRTX | ▼ Sell | Open Market | 172 | $60K | 5/2/2023 | View on chart |
| VRTX | ▲ Buy | Grant | 1,168 | $0 | 5/1/2023 | View on chart |
| VRTX | ▼ Sell | Open Market | 621 | $193K | 10/24/2022 | View on chart |
| VRTX | ▼ Sell | Open Market | 164 | $48K | 8/8/2022 | View on chart |
| VRTX | ▼ Sell | Open Market | 204 | $60K | 8/8/2022 | View on chart |
| VRTX | ▼ Sell | Open Market | 161 | $47K | 8/8/2022 | View on chart |
| VRTX | ▼ Sell | Open Market | 47 | $14K | 8/8/2022 | View on chart |
| VRTX | ▼ Sell | Open Market | 45 | $13K | 8/8/2022 | View on chart |
| VRTX | ▼ Sell | Open Market | 99 | $27K | 7/29/2022 | View on chart |
| VRTX | ▼ Sell | Open Market | 200 | $56K | 7/29/2022 | View on chart |
| VRTX | ▼ Sell | Open Market | 160 | $45K | 7/29/2022 | View on chart |
| VRTX | ▼ Sell | Open Market | 99 | $28K | 7/29/2022 | View on chart |
| VRTX | ▼ Sell | Open Market | 58 | $16K | 7/29/2022 | View on chart |
| VRTX | ▼ Sell | Open Market | 5 | $1K | 7/29/2022 | View on chart |
| VRTX | ▼ Sell | Open Market | 40 | $10K | 5/2/2022 | View on chart |
| VRTX | ▼ Sell | Open Market | 280 | $72K | 5/2/2022 | View on chart |
| VRTX | ▼ Sell | Open Market | 120 | $31K | 5/2/2022 | View on chart |
| VRTX | ▼ Sell | Open Market | 120 | $31K | 5/2/2022 | View on chart |
| VRTX | ▼ Sell | Open Market | 80 | $21K | 5/2/2022 | View on chart |
| VRTX | ▼ Sell | Open Market | 6 | $2K | 5/2/2022 | View on chart |
| VRTX | ▼ Sell | Open Market | 91 | $24K | 5/2/2022 | View on chart |
| VRTX | ▲ Buy | Grant | 1,449 | $0 | 5/1/2022 | View on chart |
| VRTX | ▼ Sell | Open Market | 1,907 | $534K | 4/8/2022 | View on chart |
| VRTX | ▲ Buy | Option Exercise | 1,907 | $240K | 4/8/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Vertex Highlights Sickle Cell Gene Therapy and Hormone Disorder Expansion
Vertex Pharmaceuticals is advancing a gene therapy for sickle cell disease, which could broaden its treatment portfolio but faces access challenges. The company also signals a potential new growth area in hormone disorders, moving beyond cystic fibrosis. With earnings approaching, investors are watching how these developments affect the company’s outlook. The stock has risen above the market recently, reflecting positive sentiment.
Vertex Highlights Sickle Cell Gene Therapy and Hormone Disorder Expansion. Vertex Pharmaceuticals is advancing a gene therapy for sickle cell disease, which could broaden its treatment portfolio but faces access challenges. The company also signals a potential new growth area in hormone disorders, moving beyond cystic fibrosis. With earnings approaching, investors are watching how these developments affect the company’s outlook. The stock has risen above the market recently, reflecting positive sentiment.